Pullman Shanghai South Shanghai -...

15 May, 2017

Pullman Shanghai South

Shanghai

S h o w c a s e

Fenglin Forum

http://www.sebpchina.com

I n v e s t m e n t

P a r t n e r i n g

I n n o v a t i o n

Sino-Euro BioPartnering (SEBP) is an annual conference which provides a cost-effective and tailor-made partnership platform for European and other international SMEs to partner with local companies and investors.

SEBP was first launched by G-Med Consulting, Bioclouds, Biowin Lyonbiopole and Juke Science Park in 2013 in Shanghai. Since then, the organizers have successfully organized four conferences, and supported numerous of industry leaders and investors. The organizers offer pre-selection, onsite support and follow up services for European and US participants and have established strong network with bioclusters, academia, hospitals, industry and the investment societies.

Biotech, Pharma & Medtech

Industry Trend and Insight Investment

Guide in Europe & US

Europe & US SME Showcase

Customized Partnering Platform

Academic - Hospital - Industry

15th May, 2017 Pullman Shanghai South

SAVE THE DATE!


Partnership: Research – Clinic – Business – Investment

SEBP2017Agenda

Sino-Euro BioPartnering 2017

15th May, 2017 Monday

Site:Pullman Shanghai South

08:00--09:00 Registration

09:00--09:30 Opening

Address by Xuhui MayorAddress by Dr. Ioana Kraft ,General Manager , European Union Chamber of Commerce in ChinaAddress by Dr. Filippo Belardelli, Vice President, ALISEI bioXclusters China Gateway signing ceremony

09:30--10:30 Plenary

09:30-09:50Keynote 1: “Opportunities and Challenges of the future biomedical industry under the new medical policy in China” by Mr. Mingde YU, Chairman, China Pharmaceutical Enterprises Association

09:50-10:10 Keynote 2: “Precision Medicine in Drug Discovery” by Dr. Mingqiang ZHANG, Vice President of Amgen’s Asia R&D Center

10:10-10:30 Keynote 3: “The Successful Cross Boarder Partnership in China” by Mr. Valtero Canepa,General Manager, JV Bracco Sine Pharmaceuticals

10:30--10:50 Coffee break

10:50--11:10 Presentation

Presentation: “The Fenglin BioMedical Center" by Ms. Daisy TAO, Executive Director, Fenglin BioMedical Center

Presentation: “The bioXclusters meta-cluster” by Mr. Fabrizio Conicella, General Manager, Bioindustry Park Silvano Fumero S.p.A, bioXclusters representative

11:10--12:00 Showcase I Session I (3 projects)Moderator: Mr. Ronghui GAO, Managing Director, Fenglin BioMedical Center

12:00--13:00 Lunch Lunch and network

Panel Discussion I

Panel discussion 1: “How can innovation improve precision medicine?” Moderator: Dr. Mingde XIA, Senior Director, J&J Innovation Center, Shanghai

13:00--13:40

Ke Hua Bio-EngineeringLide Biotech3S Bio Inc. WuXi AppTec Lv Ye Pharma

13:40--14:40 Showcase IISession II (5 projects)Moderator: Mr. Brett Johnson, CEO, OneMed Market

14:40--14:55 Coffee break


Partnership: Research – Clinic – Business – Investment

SEBP2017Agenda

Sino-Euro BioPartnering 2017

15th May, 2017 Monday

Site:Pullman Shanghai South

14:55--15:40 TopicPanel Discussion II

InvestmentPanel discussion 2: “Cross border partnership and investment opportunities”Moderator: Mr. Fabrizio Conicella, General Manager, Bioindustry Park Silvano Fumero S.p.A, bioXclusters representativeRoche DiagnosticsXin Hua MedicalSinopharm SanPower GroupVirtus Inspire Capital

15:40--17:10 Showcase IIISession III (6 projects)

Moderator: Dr. Jiong ZHANG, General Manager, Shanghai Juke Biotech Park

17:10--17:20 Closing Summary

-------- Invitation Only-------

16th May, 2017 Tuesday

Site: Fenglin International Plaza

09:00--09:05 Opening Mr. Yinfei WU, President, Fenglin Life Healthcare Group

09:05--09:20 Keynote: “Overview of China Biomedical Industry” by Ms. Tina HOU, Associate Partner, McKiensey & Co.

09:20--10:20

Hopsital Introduction

Zhongshan Hospital (Affiliated to Fudan University Medical College)No.6 People's Hospital (Specialty on Diabetes and Othorpedics) Shanghai Xuhui Central Hospital

10:20-10:35 Coffee break

10:35--11:05 Panel

Topic: Clinical trial and registration in China

Moderator: Mr. Ronghui GAO, Managing Director, Fenglin BioMedical Center

Quintiles IMS

Han Kun Law Office

Mid-Link

JyTon

11:05--11:35 Company introduction: Shanghai Pharm, Yangzi River Pharm, Comermy Plc

11:35--13:00 Lunch Lunch and network 13:00--13:30

VisitVisit Fenglin BioMedical Center

13:30--14:30 Visit Shanghai Institute of Organic Chemistry, CAS 15:00--16:30 Visit Shanghai Xuhui Central Hospital

17:00--17:10 Closing Summary


A TAILORED PLATFORM FOR COLLABORATION

MEET WITH THE RIGHT LOCAL PARTNERS| Some major participants in 2017

Hospitals & Institutes

Pharmaceuticals

Medical Device Companies

CROs

Consulting

ProjectsCountry Sector Summary Interest

Germany IVD

Company has developed a diagnostic method, which determines for individual cancer patients the optimally effective drug therapy taking into account the individually characteristic tumor properties. Clinical trial for breast cancer successfully completed, clinical trials for colon, gastric and ovarial cancer: recruiting finished。

Funding & Partnership

Switzerland Medical service

VR based system for rehabilitation. The solution is a networkable bionic training technology - consisting of software, cloud based applications and robotic hardware with a targeted focus on (re)- establishing and maintaining mobility, independence in activities of daily living and quality of life. Test market includes 30 hospitals, rehabilitation and medical sports institutions, where the devices administer 60’000+ training sessions yearly, on 3’000+ users, with100+ new users per week

Funding & distributor

Switzerland Nutraceutical

The company discovers and provides innovative, high-value, sustainable ingredients, with an emphasis on health, wellness and nutrition. One key product stilbenoid with anti-inflammatory and antioxidant properties, has been shown to have beneficial effects on bone loss in two clinical and numerous preclinical studies.

Funding & partnership

UK IVD

Early cancer detection by using detecting autoantibodies in blood. Broad IP protection of cancer autoantibodies for Dx applications. Lung cancer test has demonstrated superior performance in 10,000 patient study.Test can detect cancer up to 4 years earlier than other methods.Utility as screening assay for high-risk individuals (smokers)Tests for liver and ovarian cancers in development. Commercially available in the U.S. (CLIA lab) and Europe (CE). 125,000 commercial tests sold to date

Funding & partnership

Portugal Pharmaceutical

Company specialist expertise in the process chemistry to address the complex issues associated with the development and production. The company provides Contract Manufacturing Services on: Drug Substance Particle Engineering Drug Product Proprietary Product Licensing: dermatology, ophthalmology, respiratory


US Medical Device

Life Care Magnetics LCM-1510k clearance: “to generate deep heat within body tissues for the treatment of medical conditions…”•Next Generation Aesthetic Medicine Device•Novel energy system for heat based aesthetic therapy•Treats deep tissues without damaging skin

Funding & partner

Germany Drug DeliveryThe company is the leader in transdermal therapy systemsand oral thin films. As a B2B partner to the pharmaceutical industry, the company offers solutions at all stages of drug development.

Co-development partner

US Biotech

A medical technology company engaged in cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration. The company develops and processes biologic allograft products. The company is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration

Licensing & distributor

US Biotech

The company is paving the way for the development of advanced gene-editing medicines to treat HIV. Its approach made use of the gene editing technology to locate the HIV-1 DNA in the T-cell, and edit the nuclease enzyme. This led not only to eradication of the virus, but perhaps more significantly, a shield against reinfection.

Funding & distribution

US PharmaceuticalThe company has received FDA approval of an oral, extended-release tablet with abuse-deterrent properties, creating the potential for a large-scale reduction in overdoses connected with prescription opioid abuse.

Distribution

ProjectsCountry Sector Summary Interest

US IVD

The company focuses on unmet cancer diagnosis and treatment needs. Specifically, the company has developed a blood test, to be used in the early detection of breast cancer in women with dense breast tissue whose cancers are missed 50% of the time. Beyond breast cancer, the company is also involved in research aimed at treating pancreatic cancer.

Funding & Partnership

US Medical Device

Next Generation Aesthetic Medicine Device. 510(k) FDA clearance for treatment of numerous tissue conditions. -1st-Revenue & near-term revenue opportunity, extensive follow on product pipeline: •Novel energy system for heat based aesthetic therapy•Treats deep tissues without damaging skin•Advantages over RF and ultrasound


US Medical Device

Company provides cutting edge targeted localized radiation, with proprietary unidirectional gold shielding. Commercially available• First in man 2013• Prostate, colorectal, pelvic region, head and neck,pancreatic cancers• 96% less radiation to surrounding health tissue• Zero radiation related toxicities• Simple, repeatable, safe


US Medical Device

The company leverages academic bioengineering, surgical expertise, micro engineering manufacturing and nano technology to provide the modern solution for the vexing problem of glaucoma. Nonclinical and animal tests show the company’s device, implanted through the eye’s surface, halts the progression of glaucoma, which can cause blindness. The device, which houses nano-engineered flow channels to shunt fluid from inside the eye to reduce pressure that damages the optic nerve, is the thickness of about 1½ human hairs.

Funding

US Biotech

The company is developing innovative tissue regeneration products from biologic sources for chronic wounds, as well as for hernia and joint repair. The company’s first product using its bridge tissue regeneration technology, a collagen matrix that heals chronic skin wounds faster compared to other skin substitutes.

Funding & distribution

US Biotech

The company is a regenerative medicine company, made a discovery that growing newborn skin cells under embryonic conditions of low oxygen and suspension, they rapidly become multi-potent stem cells. They secrete soluble and insoluble materials that are very embryonic that are able to stimulate stem cells throughout the body. We collect both of the products simultaneously. The lead product is an injectable, and two trials with excellent safety and efficacy

Funding & partner


Sponsorship Packages

Platinum Diamond Gold Silver

RMB 200,000 RMB 100,000 RMB 50,000 RMB 20,000

Registration

Free passes 10 5 3 3

Panel discussion

Panelist yes yes - -

Showcase yes yes - -

Presentation slot 1 1 1 -

Booth and logo display

Booth* yes yes - -

Logo on name tag yes yes yes -

Logo on brochure yes yes yes -

Logo on backdrop yes yes yes -

Logo on website yes yes yes yes

Promotion

Roll up poster 2 1 1 -

Advertisement on brochure One page One page One page Half page

Leaflet in bag yes yes yes -

Partnering

Prearranged meeting yes yes yes yes

Project follow up

Project information yes yes - -

SEBP2017Sponsorship


A TAILORED PLATFORM FOR COLLABORATION

| Previous Chinese participants

| Previous European participants

SIMPLY MEET WITH THE BESTS

SINOPHARM • WISON • FOSUN PHARMA • KEHUA • BIOMABS • DIAN DIAGNOSTICS • CP GUOJIAN • SUNDIA • UPPER BIOTECH • FRONTAGE • SHENZHEN TIME BOLE • HISUN PHARMA • HD BIOSCIENCES • SHANGHAI PHARMA • 3SBIO • WUXI APPTEC • SHANGPHARMA • MINDRAY • TIGERMED • NUOKANG BIOPHARM • T-MAB • FOUNTAINVEST PARTNERS • HUA MEDECINE • AB MART • ORBIMED • MEDICILON • WALVAX • MICROPOT • OMAHA CAPITAL • SHANGHAI BIOCHIP • BAYCITY CAPITAL • DAAN GENE • BSK VENTURES • ASCENTAGE PHARMA • WONDFO • HUA PHARMA • GENOR BIOPHARMA • YANGTZE RIVER PHARMA • PIONEER PHARMA • LUYE PHARMA • KEYBAY • SIMCERE • HENGRUI MEDICINE • OSMUNDA • BEIXING CAPITAL • YUYUE • CHAI TAI TIANQING PHARMA • CROWNBIO • DT CAPITAL • EDDINGPARM • KINGMED DIAGNOSTICS • MORNINGSIDE • PHARMALEGACY • QIMING VENTURE • HENLIUS BIOTECH • ZERUN BIOTECH • CHINA GRAND • TASLY • WEGO • GREATER PACIFIC CAPITAL • FARMASINO • CHINA GRAND • FOSUN DIAGNOSITICS • JIUZHOU PHARM …

• Distributors• Pharma• Investors

• Medtech / IVD• CMO/CRO• Biotech


EUROPEAN AND US SME FOCUS

| Key topics:

|Showcase:

“Opportunities and Challenges of the future biomedical industry under the new medical policy in China”

LINK

“I attended SEBP 2013 in Shanghai: I had a very positive impression. In my opinion, it is the right place to meet the Chinese scientific community, to share opinions and business opportunities, which must then be consolidated in several separate meetings. However, the proactive and informal atmosphere is very productive, and is a great facilitator for the first contacts between different cultures and business styles. I consider the participation to SEBP a great opportunity and the right investment for companies willing to explore potential partnerships into China.”

Dr. Domenico CriscuoloCEO Genovax (Italy)

“SEBP is a specialized partnering fair selecting specific spotlight topics of interest and which provides unique opportunity to share not only China market insights but also European biotech and medical company’s development and commercial focus. We did attend the conference several time, presenting our new products and technologies to Chinese potential partners specially during the roadshow. These presentations were often followed by B2B discussions and did initiate business opportunities. We do appreciate the conference and wish great success in the following years.”

Dr.Thierry Leclipteux CEO Coris BioConcept (Belgium)

“Cross border partnership and investment opportunities”

About twenty innovative companies from Europe, US and China will present their projects and business interests in drug development, biotech, IVD and medical devices sectors; Over 300 attendees from the industry and investment community will attend the conference

“The precision medicine impact to the global pharmaceutical industry development”

“How can innovation improve precision medicine?”

“Precision medicine practice in the cancer treatment”


REGISTRATION

[email protected] look forward to seeing you at SEBP2017!

Partners

Early Bird(before 30th April)

Regular(after 30th April)

On site(15th May) Description

Conference pass

m Industry, Investor, Services350 Euros *

OR2600 RMB

400 Euros*OR

3000 RMB3500 RMB***

Conference pass gives access to keynote speeches, panel discussions, showcase and partnering sessions. The conference also provides simultaneous translation, buffet lunch & coffee break

m Academia, Organisation300 Euros*

OR2200 RMB

350 Euros*OR

2600RMB

Company presentation

q Presentation Subject to application**

Subject to application** NA

Company will be given 10 minute slot to present its company (Each slot is limited for one company)

* per person ** per company (in addition to registration fee)*** Price per person, payable in RMB onlyTo enjoy the early bird rate, please register and arrange the payment before 16th of April.

Please register： www.sebpchina.com

http://www.pullman-zx.com/

Room （RMB） Free

Superior King Room 900 1 Breakfast and Internet

1,000 2 Breakfast and Internet

Superior Twin Room900 1 Breakfast and Internet

1,000 2 Breakfast and Internet

Pullman Shanghai South HotelHotels combining lifestyle and design, for business and leisurePullman Shanghai South is an international upscale business hotel, situated in ZStar Plaza in the new CBD of Shanghai Xuhui District with easy access to Shanghai South Railway Station and Shanghai National Convention & Exhibition Center. The hotel has 333 contemporary rooms and suites, an executive lounge, spa, gym and indoor swimming pool. It has 3 restaurants and 2 bars and meeting facilities that include a 1300sqm ballroom and 7 function rooms.

Pullman Shanghai South Shanghai -...

Documents

Transcript of Pullman Shanghai South Shanghai -...